Skip to main content

16-153 A phase II clinical trial evaluating the efficacy of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients previously treated with PD-1-directed therapy

NCT03014648

A phase II clinical trial evaluating the efficacy of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients previously treated with PD-1-directed therapy

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

University of Pittsburg Medical Center

The main goal of this research study is to determine if atezolizumab prevents your lung cancer from growing and for how long. If you decide to participate in this study, you will be assigned to a group based on how well your cancer responded to nivolumab or pembrolizumab. This is being done to better track if your response to atezolizumab is different than your response to those drugs.

This study is currently enrolling.